Age-Related Macular Degeneration

Eyes with bacillary detachment had higher fluid volumes, increased CST, EZ attenuation, and increased sub-RPE volume at baseline.

Close to half of patients with wet AMD treated with aflibercept could safely stop eye injection therapy after one year without further vision loss, according to the pilot study.

A look back at 2022, including new drug approvals, the significance of treatment for geographic atrophy, and what the future holds within the retina space. Veeral Sheth, MD joins to discuss in a Q&A.

The results from the artificial intelligence deep learning model indicated alterations in the SD-OCT imaging regions attributed to the retinal nerve fiber and choroid layers.

A post-hoc analysis of the HARBOR trial suggest a greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution.

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

Study data indicate the AI-based follow-up system could make an autonomous decision in 73% of the cases, of which 91.8% were in agreement with retina experts consensus.

No difference was seen in the odds of tractional retinal detachment between those with a loss to follow-up period of 6 months or longer and those without loss to follow-up.

The study data indicate high early-stage CRT variability showed a significantly higher risk of legal blindness.

The introduction of brolucizumab resulted in savings in the manufacturer-recommended and real-world evidence regimens.

Low luminance contrast sensitivity was significantly more reduced in nGA eyes than in eyes with drusen alone, but no differences were seen when assessing other cone functions with normal luminance CS or LLVA

Dry AMD was more common than wet AMD, but visual acuity was more significantly affected in patients with wet AMD.

The shared genetic structure and pleiotropic mechanisms in ocular diseases interprets their clinical associations to some extent, according to study authors.

The result show the gain in best-corrected visual acuity and the reduction in central subfield thickness at the conclusion of the core study was maintained up to week 24 of the extension study, with no differences in the safety profile.

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.

Enhanced ellipsoid integrity, greater outer retinal thickness, and decreased GA were associated with increased BCVA gains with risuteganib.

All ocular treatment-emergent adverse events were intravitreal injection related and mild or moderate in severity.

A faster rate of visual field progression was observed among 37 glaucomatous eyes treated with anti-VEGF for nAMD compared with a control group of 4304 eyes without anti-VEGF.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.

A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.

Serious forms of cardiovascular diseases were observed to be connected to a specific form of AMD with subretinal drusenoid deposits.

The novel investigational complement C5 inhibitor is the only product for treatment of geographic atrophy to achieve two positive phase 3 pivotal trials with statistical significance.

The apolipoprotein E ε2/ε3/ε4 variant was associated with a significant linearly increasing trend for risk of AMD from ε4 to ε3 to ε2.

Similar visual and anatomical outcomes were observed through 1 year, despite fewer injections in the mandated quarterly treated group.

Anti-brolucizumab ADAs may be a risk factor for intraocular inflammation and retinal occlusive vasculitis in patients treated with brolucizumab.

Approximately 20 million individuals in the US were living with AMD in 2019, including 18.34 million with early-stage AMD and 1.49 million with late-stage AMD.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.

An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.